Sostenibilità. Facciamo sul serio.
Thought leadership

Tackling post

Pandemic pharmaceutical challenges

EOS Insight
22 April 2021 |
A panel debate on the role of companies and investors

Last month we looked at post-pandemic pharmaceutical challenges as part of a panel session we hosted for the US Council of Institutional Investors (CII) virtual Spring 2021 conference.

Moderated by Katie Frame, our other engagers Dr Emma Berntman and Sarah Swartz were joined by Damiano de Felice, director of strategy at the Access to Medicine Foundation and Silas Holland, head of communications and external affairs at the AMR Action Fund.

The pandemic has highlighted the vulnerability of our healthcare systems and inequities in access to them. So we asked what can companies and investors do to mitigate these issues? What did we learn along the way in the race for the vaccine? And what has the pandemic shown in terms of links between the sustainability agenda and human health?

We take a global approach to engagement with companies so our panel applied an international lens to looking at these challenges, as well as wider issues such as antimicrobial resistance and equitable vaccine distribution. Inviting questions from the audience, make sure you catch up with this session to hear why companies and investors need to step up to tackle pharmaceutical challenges in a post-pandemic world.

Watch the recording in full below or click to jump to a section.

Related insights

Lightbulb icon

Get the latest insights straight to your inbox